deutetrabenazine for the treatment of chorea associated with Huntington’s disease
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating chorea associated with Huntington’s disease. Unfortunately, treatment has been limited for many aspects of this neurodegenerative disease. The present investigation presents the background, evidence, and indications for the use Deutetrabenazine in the setting of Huntington’s disease. Huntington’s disease is characterized by a variety of motor, psychiatric, and cognitive symptoms with chorea being one of the more notable ones. Chorea is a movement disorder present in multiple neurologic diseases that causes involuntary and irregular muscle movements theorized to be stemming from high dopamine levels. Deutetrabenazine is thought to function as an inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased monoamine release, including dopamine, in the synaptic cleft which has a therapeutic effect in management of chorea. This drug was approved by the FDA in 2017 with a specific indication for tardive dyskinesia and choreiform movement in Huntington’s disease. Currently, there is no definitive treatment for Huntington’s disease. Thus, management is primarily focused on symptom management with the use of a variety of pharmaceutical agents. Chorea is one of the many manifestations that significantly alter the quality of life of many patients. Deutetrabenazine is a promising new option for the treatment of chorea in the setting of Huntington’s disease. Although studies so far have displayed mixed results, further research, including head-to-head studies, is necessary to elucidate the true potential of this drug.
1. Walker RH. Chorea. CONTINUUM. 2013;19:1242-1263. doi:10.1212/01.con.0000436155.46909.c3
2. Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218-228. doi:10.1016/s0140-6736(07)60111-1
3. Cardoso F. Huntington Disease and Other Choreas. Neurologic Clinics. 2009;27(3):719-736. doi:10.1016/j.ncl.2009.04.001
4. Dean M, Sung V. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease. Drug Des Dev Ther. 2018;12:313-319. doi:10.2147/dddt.s138828
5. Snowden JS. The Neuropsychology of Huntington’s Disease. Arch Clin Neuropsychol. 2017;32(7):876-887. doi:10.1093/arclin/acx086
6. McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25(1):24-34. doi:10.1111/ene.13413
7. Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington’s disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011;198:252-273. doi:10.1016/j.neuroscience.2011.08.052
8. Lee JM, Wheeler VC, Chao MJ, et al. Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease. Cell. 2015;162(3):516-526. doi:10.1016/j.cell.2015.07.003
9. Ghosh R, Tabrizi SJ. Clinical features of huntington’s disease. In: Advances in Experimental Medicine and Biology. Springer International Publishing; 2018:978-973. https://doi.org/10.1007/978-3-319-71779-1_1
10. Jankovic J, Roos RAC. Chorea associated with Huntington’s disease: to treat or not to treat? Mov Disord. 2014;29(11):1414-1418. doi:10.1002/mds.25996
11. Coppen EM, Roos RAC. Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease. Drugs. 2017;77(1):29-46. doi:10.1007/s40265-016-0670-4
12. Suchowersky O, Armstrong MJ, Miyasaki J. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;80(10):970-970. doi:10.1212/wnl.0b013e3182885eb3
13. Sung VW, Iyer RG, Gandhi SK, et al. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States. Curr Med Res Opin. 2018;34(4):643-648. doi:10.1080/03007995.2018.1435518
14. Schmidt C. First deuterated drug approved. Nat Biotechnol. 2017;35(6):493-494. doi:10.1038/nbt0617-493
15. Bashir H, Jankovic J. Deutetrabenazine for the treatment of Huntington’s chorea. Expert Rev Neurother. 2018;18(8):625-631. doi:10.1080/14737175.2018.1500178
16. Wyant KJ, Ridder AJ, Dayalu P. Huntington’s Disease—Update on Treatments. Curr Neurol Neurosci Rep. 2017;17(4):1-11. doi:10.1007/s11910-017-0739-9
17. Edwards TC, Zrinzo L, Limousin P, Foltynie T. Deep brain stimulation in the treatment of chorea. Mov Disord. 2012;27(3):357-363. doi:10.1002/mds.23967
18. Reilmann R. Pharmacological treatment of chorea in Huntington’s disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013;28(8):1030-1033. doi:10.1002/mds.25500
19. Drugs@FDA: FDA-Approved Drugs. Accessed December 5, 2021. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209885
20. Schmidt C. First deuterated drug approved. Nat Biotechnol. 2017;35(6):493-494. doi:10.1038/nbt0617-493
21. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Published April 2, 2019. Accessed December 5, 2021. https://www.ncbi.nlm.nih.gov/books/NBK548187/
22. Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharm. 2019;42(2):37-41. doi:10.1097/wnf.0000000000000326
23. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461-2470. doi:10.1080/14656566.2016.1258063
24. Carvedilol Therapy and CYP2D6 Genotype - PubMed. Accessed December 6, 2021. https://pubmed.ncbi.nlm.nih.gov/30067327/
25. Bashir H, Jankovic J. Deutetrabenazine for the treatment of Huntington’s chorea. Expert Rev Neurother. 2018;18(8):625-631. doi:10.1080/14737175.2018.1500178
26. Russak EM, Bednarczyk EM. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. doi:10.1177/1060028018797110
27. Schneider F, Bradbury M, Baillie TA, et al. Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers. Clin Transl Sci. 2020;13(4):707-717. doi:10.1111/cts.12754
28. DeWitt SH, Maryanoff BE. Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine. Biochemistry. 2018;57(5):472-473. doi:10.1021/acs.biochem.7b00765
29. Richard A, Frank S. Deutetrabenazine in the treatment of Huntington’s disease. Neurodegener Dis Manag. 2019;9(1):31-37. doi:10.2217/nmt-2018-0040
30. Frank S, Testa CM, Stamler D, et al. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016;316(1):40-50. doi:10.1001/jama.2016.8655
31. Frank S, Stamler D, Kayson E, et al. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017;74(8):977-982. doi:10.1001/jamaneurol.2017.1352
32. Walker RH. Chorea. CONTINUUM. 2013;19:1242-1263. doi:10.1212/01.con.0000436155.46909.c3
33. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. doi:10.1016/s2215-0366(17)30236-5
34. Claassen DO, Carroll B, de Boer LM, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4(1). doi:10.1186/s40734-017-0051-5
35. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: Twins or Distant Cousins? Mov Disord Clin Pract. 2017;4(4):582-585. doi:10.1002/mdc3.12483
36. Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington’s disease: a review of clinical trial data. Expert Opin Pharmacother. 2019;20(18):2209-2221. doi:10.1080/14656566.2019.1674281
37. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.” J Clin Mov Disord. 2017;4(1):1-3. doi:10.1186/s40734-017-0067-x
38. Dean M, Sung V. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease. Drug Des Dev Ther. 2018;12:313-319. doi:10.2147/dddt.s138828
39. Rodrigues FB, Wild EJ. Huntington’s Disease Clinical Trials Corner: February 2018. J Huntington’s Dis. 2018;7(1):89-98. doi:10.3233/jhd-189001